Multi-Omics for Rare Kidney Diseases: A systematic review

Rare kidney diseases (RKDs) account for 5–10% of people with chronic kidney disease, collectively affecting millions of people globally. RKDs comprise the majority of childhood kidney disease, disproportionately responsible for ~ 60% of children who need kidney replacement therapy. RKDs are primarily genetic, so further understanding the molecular mechanisms behind these diseases is crucial to earlier diagnosis, better treatment, and increasing quality of life. Multi-omic approaches provide an opportunity to identify and exploit novel biomarkers and therapeutic targets to aid in the management of RKDs. The aim of this systematic review is to summarise and evaluate biomolecular multi-omic studies for RKDs internationally from 2014 to 2025. This systematic review completed searches on PubMed, SCOPUS, Web of Science, BioRxiv and MedRxiv for studies relevant to ‘Rare Kidney Disease’ and ‘Multi-omics’ published before the 24th of February 2025. Screening was performed using the Covidence platform, after which data extraction was completed using a customised tool for 19 studies. Of note, neither generic terms ‘rare disease’ or ‘rare kidney disease’ were included in the title, abstract, or keyword elements of the articles through to final extraction, highlighting the need to search for each individual kidney disease individually. Of the 75 RKDs included in the scope of this review, six diseases have a multi-omic study, and 63% of these studies related to one disease, IgA Nephropathy. Whilst ~ 80% of rare disease have a genetic origin, less than 50% of these studies utilised genetically driven omics technologies. The findings of this review highlight a gap in the research base but also point to opportunities to utilise multi-omic approaches to drive molecular research for RKDs. Additionally, it reinforces the need for future research on rare diseases to include explicit terms such as ‘rare disease’ or ‘rare condition’ in the title, abstract or keywords to maximise their impact and ensure their consideration in future reviews on rare diseases.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-10741167/v1
Primary Topic
Renal Diseases and Glomerulopathies
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Multi-Omics for Rare Kidney Diseases: A systematic review

Charuhas V. Thakar, Laura Jane Smyth, Christopher Wooster, Amy Jayne McKnight et al.
Research Square
Renal Diseases and Glomerulopathies
preprint

Multi-Omics for Rare Kidney Diseases: A systematic review

Charuhas V. Thakar, Laura Jane Smyth, Christopher Wooster, Amy Jayne McKnight, Thomas J. Cahill, Erin Feehily, Shea Walsh
preprint en

Abstract

Rare kidney diseases (RKDs) account for 5–10% of people with chronic kidney disease, collectively affecting millions of people globally. RKDs comprise the majority of childhood kidney disease, disproportionately responsible for ~ 60% of children who need kidney replacement therapy. RKDs are primarily genetic, so further understanding the molecular mechanisms behind these diseases is crucial to earlier diagnosis, better treatment, and increasing quality of life. Multi-omic approaches provide an opportunity to identify and exploit novel biomarkers and therapeutic targets to aid in the management of RKDs. The aim of this systematic review is to summarise and evaluate biomolecular multi-omic studies for RKDs internationally from 2014 to 2025. This systematic review completed searches on PubMed, SCOPUS, Web of Science, BioRxiv and MedRxiv for studies relevant to ‘Rare Kidney Disease’ and ‘Multi-omics’ published before the 24th of February 2025. Screening was performed using the Covidence platform, after which data extraction was completed using a customised tool for 19 studies. Of note, neither generic terms ‘rare disease’ or ‘rare kidney disease’ were included in the title, abstract, or keyword elements of the articles through to final extraction, highlighting the need to search for each individual kidney disease individually. Of the 75 RKDs included in the scope of this review, six diseases have a multi-omic study, and 63% of these studies related to one disease, IgA Nephropathy. Whilst ~ 80% of rare disease have a genetic origin, less than 50% of these studies utilised genetically driven omics technologies. The findings of this review highlight a gap in the research base but also point to opportunities to utilise multi-omic approaches to drive molecular research for RKDs. Additionally, it reinforces the need for future research on rare diseases to include explicit terms such as ‘rare disease’ or ‘rare condition’ in the title, abstract or keywords to maximise their impact and ensure their consideration in future reviews on rare diseases.

Research Square
Queen's University Belfast (GB)
Renal Diseases and Glomerulopathies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon